RAPT THERAPEUTICS INC. - COMMON STOCK

1,0800

22-ноября-24 16:44:58

15 мин. задержка

Акции

+0,0300

+2,86%

Сегодняшний диапазон

1,0400 - 1,1200

ISIN

N/A

Источник

NASDAQ

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

12 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

11 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2024 Financial Results

08 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Reports First Quarter 2024 Financial Results

09 май 2024 08:00:01 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

09 апр 2024 12:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

07 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

05 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

20 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

13 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

31 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

27 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2023 Financial Results

13 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

03 ноя 2023 12:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

01 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

18 окт 2023 09:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

30 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results

11 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

07 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

25 май 2023 17:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.